Geode Capital Management
IMPL

Geode Capital Management’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Geode Capital Management’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-172,218
Closed -$74.1K – 4727
2023
Q3 		$74.1K Buy
172,218
+17,258
+11% +$16.6K ﹤0.01% 4324
2023
Q2 		$197K Buy
154,960
+570
+0.4% +$864 ﹤0.01% 4046
2023
Q1 		$216K Buy
154,390
+152
+0.1% +$363 ﹤0.01% 4011
2022
Q4 		$578K Buy
154,238
+5,592
+4% +$20.4K ﹤0.01% 3597
2022
Q3 		$723K Buy
148,646
+33,461
+29% +$256K ﹤0.01% 3550
2022
Q2 		$1.07M Sell
115,185
-46,604
-29% -$340K ﹤0.01% 3389
2022
Q1 		$1.03M Buy
161,789
+32,989
+26% +$249K ﹤0.01% 3610
2021
Q4 		$1.11M Buy
128,800
+10,884
+9% +$109K ﹤0.01% 3670
2021
Q3 		$1.44M Buy
117,916
+66,974
+131% +$972K ﹤0.01% 3507
2021
Q2 		$450K Buy
+50,942
New +$608K ﹤0.01% 3990

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Geode Capital Management's IMPL Position: Q4 2023 in Review

Geode Capital Management sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 172,218 shares — an estimated $74.1K sold.

Geode Capital Management first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $1.44M in Q3 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • Geode Capital Management reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Geode Capital Management sold 172,218 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $74.1K.
  • Geode Capital Management first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Geode Capital Management's Impel Pharmaceuticals Inc. Common Stock position peaked at $1.44M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.